NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.…
NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data
NeuroSense Therapeutics (NASDAQ: NRSN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 17 employees.
The shares were at 1.280 USD on 20 November 2026, down 93.4% over 52 weeks. Its 52-week range is 1.100 USD to 25.40 USD: the price is 95.0% below the high and 16.4% above the low.
Its market capitalisation is 3.19M USD.
NeuroSense Therapeutics reports an operating margin of 0.0%.
Its debt exceeds its cash by 4.00K USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.